Whereas a clinical application of synthetic PSMA-PET in patients with biochemical PSA value recurrence, in which identification of single lesions is crucial, is not possible because of limited sensitivity (Table 2), a potential use case is frequent re-stating of patients with high PSMA-avid tumor burden undergoing PSMA radioligand therapy, in whom assessment of therapy response might be possible [27]. The gene discussed is FOLH1; the disease is neoplasm.